Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.

ABSTRACT:

Background

Mutated circulating cell-free DNA (cfDNA) has been suggested as a surrogate marker of tumour burden and aggressiveness of disease. We examined the association between the level of plasma mutant cfDNA and metabolic tumour burden (MTB) measured by ¹⁸F-fluoro-D-glucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT). Furthermore, the presence of mutant cfDNA was correlated with patient survival.

Methods

Forty-six advanced non-small cell lung cancer (NSCLC) patients were included. At the time of inclusion, blood sampling and a PET/CT scan were performed. cfDNA was isolated and next-generation sequencing (NGS) was performed (Ion AmpliSeq Colon and Lung Cancer panel v2). MTB was defined by a volumetric PET parameter.

Results

SUBMITTER: Winther-Larsen A 

PROVIDER: S-EPMC5572172 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature